Endocrine Abstracts

Introduction: Treatment with dopamine agonists in patients with prolactinomas and Parkinson’s disease is associated with central side effects. Central side effects may depend on a substance’s ability to pass the blood-brain barrier which can be actively controlled by transporter molecules such as the P-glycoprotein encoded by the ABCB1 gene.Aim of the study: To determine whether cabergoline is transported by the P-glycoprotein and whether polym...